Should Boards Consider Poison Pills During COVID-19?

Inside Americas Boardrooms
In this episode, Amy Simmerman & Douglas Schnell review the governance and fiduciary duties surrounding rights plans and poison pills.

For many companies, COVID-19 challenges extend far beyond health and safety. Following the pandemic's onset, many listed companies saw their stock value drop significantly. In turn, boards and management teams are focused on protecting the company from unfriendly acquirers, which has led to an increase in rights plans and poison pills.

In this episode, Amy Simmerman & Douglas Schnell, partners with Wilson Sonsini Goodrich & Rosati, review the governance and fiduciary duties surrounding these tactics:

  • What kind of protection does a rights plan provide, especially during this volatile stock market?
  • What advice do they offer boards before taking this course of action?
  • What trends are they seeing across the corporate landscape?

In a previous episode, Schnell covers: The Pros, Cons, and Controversies of Poison Pills

More episodes from Inside America's Boardrooms.

Turn ESG Promises Into Progress
Lead the way on ESG with streamlined data collection, predictive modeling, specialized dashboards and auditable reports.
Related Insights

The Rising Tide of ESG – Navigating the Road Ahead

video

The Board's Role in Leading and Enabling GRC

Article

Board and Executive Collaboration: Components of a Secure Platform for the Evolving Workplace

White Paper